ClinicalTrials.gg
CompletedNCT00550771Updated Jun 7, 2017Results posted

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

A Phase 2 interventional study of doxorubicin, cyclophosphamide, paclitaxel, trastuzumab and PLD, cyclophosphamide, trastuzumab, paclitaxel in Breast Neoplasm, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2007, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
13th of 66
181 · median 57
Started
2007
with 6 others
Phase 2
37 of 67
2 open now
Registered
23rd of 67
by date
Lead sponsor
5 of 67
Merck Sharp & Dohme LLC

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 13th largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2007, is one of 37 in phase 2, and was the 23rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the incidence of cardiac dysfunction in subjects with human epidermal growth factor receptor 2 (HER2) positive breast cancer treated with either doxorubicin or pegylated liposomal doxorubicin (PLD), both in combination with trastuzumab.

03

Conditions studied

  • Breast Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with operable, node-positive or high-risk node-negative (see #3 below) -positive breast carcinoma are eligible for the study, provided they satisfy the following criteria.

    • Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules
    • Subjects must be of female gender and >= 18 years of age
    • Subjects must have been diagnosed with operable, confirmed adenocarcinoma of the breast with no clinical or radiological evidence of disease but with otherwise high or intermediate risk tumor characteristics:

      • node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], \& M [matastases]) OR
      • node-negative AND at least one of the following features:

        • Tumor >2 cm or
        • Tumor >1 cm and

          • Negative estrogen receptor/progesterone receptor (ER/PR) or
          • Grade 2-3 or
          • Presence of peritumoral vascular invasion or
          • Age \<35 years
    • HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using

immunohistochemistry

  • Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s])
  • Baseline (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55%
  • Easter Cooperative Oncology Group ()-performance status of 0-1
  • Adequate postoperative bone marrow function with neutrophils >=1.5 x 10\^9/l, >=100 x 10\^9/l and >= lower limit of normal (LLN)
  • Adequate renal function: calculated >=50 ml/min
  • Adequate postoperative liver function with a total \< (ULN), alkaline phosphatase \<2.5 times the ULN and (AST) \<1.5 times the ULN
  • Subjects must be free of any disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations
  • Subjects of (including women who are less than one year and will be sexually active during the study) must agree to use a medically accepted method of , while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening
  • Subjects must be able to provide written

Exclusion criteria

Exclusion Criteria:

  • Subject who meets any of the following exclusion criteria will be disqualified from participation in the study:

    • Clinical or radiological evidence of disease
    • Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization
    • pericardial effusion
    • Serious cardiac illness including, but not confined to

      • history of documented congestive heart failure
      • history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy
      • history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication
      • serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias
      • clinically significant valvular disease
      • poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg)
    • Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC)
    • Pregnancy, or intending to become pregnant during the study
    • Nursing (breastfeeding) or intending to be nursing during the study
    • Any of the following clinical conditions:

      • , requiring chronic treatment
      • Clinically significant active infections
      • A history of a psychological illness of condition, preventing the subject to understand the requirements of the study
      • Unstable regulation of diabetes mellitus
    • A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study
    • Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study
    • Usage of any product within 30 days prior to enrollment
    • Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study.
    • Allergy to or sensitivity to the study drug or its
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Active comparator
    Doxorubicin Based Regimen

    Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab

  • Experimental
    Pegylated Liposomal Doxorubicin (PLD) Based Regimen

    Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel

Interventions

  • Drugdoxorubicin, cyclophosphamide, paclitaxel, trastuzumab

    Drug pages: Doxorubicin · Cyclophosphamide · Paclitaxel · Trastuzumab

    doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)

  • PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)

    Also known as: pegylated liposomal doxorubicin (SCH 200746)

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year

    Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

    Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment

Secondary outcomes

  1. Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy

    Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

    Time frame: During the 8 courses of chemotherapy

  2. Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy

    Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

    Time frame: During 1 year of trastuzumab therapy

  3. Number of Participants Who Survived Without Relapse

    Relapse-free survival would have been determined by Kaplan-Meier method. This was not calculated, since the 2 year follow-up was curtailed.

    Time frame: Approximately 2 years

07

Results

Posted Oct 3, 2011
Limitations and caveats
Any follow-up data from this study should be considered with caution as the planned 2-year follow-up was curtailed because of administrative reasons.

Participant flow

Participant flow — Overall Study
MilestonePegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based Regimen
Started12160
Completed10450
Not completed1710
Withdrew: Adverse event113
Withdrew: Discontinued for study-related reasons01
Withdrew: Physician decision20
Withdrew: Withdrawal by subject01
Withdrew: Protocol violation45

Outcome measures

PrimaryNumber of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year

Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

Time frame:
8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment
Reported as:
Number · Participants
Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year
ParticipantsPegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based Regimen
Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year511
SecondaryNumber of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy

Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

Time frame:
During the 8 courses of chemotherapy
Reported as:
Number · Participants
Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy
ParticipantsPegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based Regimen
Level 1 Cardiotoxicity10
Level 2 Cardiotoxicity13
Inability to Administer Trastuzumab00
SecondaryNumber of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy

Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of \>10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of \>10 percentage points from baseline and to \<50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.

Time frame:
During 1 year of trastuzumab therapy
Reported as:
Number · Participants
Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy
ParticipantsPegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based Regimen
Level 1 Cardiotoxicity10
Level 2 Cardiotoxicity410
Inability to Administer Trastuzumab48
SecondaryNumber of Participants Who Survived Without Relapse

Relapse-free survival would have been determined by Kaplan-Meier method. This was not calculated, since the 2 year follow-up was curtailed.

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLD Based Regimen—20/120 (16.7%)115/120 (95.8%)
Doxorubicin Based Regimen—7/59 (11.9%)58/59 (98.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPLD Based RegimenDoxorubicin Based Regimen
FEBRILE NEUTROPENIABlood and lymphatic system disorders5/1204/59
PYREXIAGeneral disorders7/1202/59
NEUTROPENIABlood and lymphatic system disorders0/1202/59
NAUSEAGastrointestinal disorders1/1202/59
VOMITINGGastrointestinal disorders0/1202/59
MALAISEGeneral disorders0/1202/59
ANAEMIABlood and lymphatic system disorders1/1201/59
CARDIAC FAILURECardiac disorders1/1201/59
MITRAL VALVE INCOMPETENCECardiac disorders0/1201/59
ABDOMINAL PAINGastrointestinal disorders0/1201/59
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPLD Based RegimenDoxorubicin Based Regimen
ALOPECIASkin and subcutaneous tissue disorders59/12045/59
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders79/1203/59
FATIGUEGeneral disorders51/12036/59
NAUSEAGastrointestinal disorders63/12035/59
NEUTROPENIABlood and lymphatic system disorders27/12026/59
MUCOSAL INFLAMMATIONGeneral disorders41/12016/59
CONSTIPATIONGastrointestinal disorders31/12020/59
RASHSkin and subcutaneous tissue disorders35/1206/59
DIARRHOEAGastrointestinal disorders34/12017/59
COUGHRespiratory, thoracic and mediastinal disorders19/12016/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based RegimenTotal
Mean50.2 ± 10.9752.5 ± 9.3250.9 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated Liposomal Doxorubicin (PLD) Based RegimenDoxorubicin Based RegimenTotal
Female12059179
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L, Richel DJ. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol. 2012 Jul;23(7):1780-8. doi: 10.1093/annonc/mdr519. Epub 2011 Nov 4. PubMed 22056854 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Aug 2010, 37 months.

Results were first posted in Oct 2011, 1 year 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 37 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Oct 30, 2007
StartActual
Jul 16, 2007
Primary completionActual
Aug 23, 2010
CompletionActual
Aug 23, 2010
Results first posted
Oct 3, 2011
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00550771
Responsible party
Sponsor
First posted
Oct 30, 2007
Start date
Jul 16, 2007
Primary completion
Aug 23, 2010
Completion
Aug 23, 2010
Results posted
Oct 3, 2011
Last update
Jun 7, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion